On December 2, 2015 Starpharma reported that AstraZeneca has selected a second DEP candidate and Starpharma will now commence a new DEP project incorporating the second proprietary AstraZeneca oncology molecule (Press release, Starpharma, DEC 2, 2015, View Source [SID:1234508807]).
The development of this new DEP candidate will be conducted under the recently signed multi-product license agreement between Starpharma and AstraZeneca. Under the agreement Starpharma has granted access for the use of its DEP drug delivery platform in the development and commercialisation of AstraZeneca compounds against a specific drug target. AstraZeneca will fund the joint program.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!